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Oncolytic viruses (OVs) offer a promising therapeutic
approach to treat multiple types of cancer. In this study, we
show that the manipulation of the antioxidant network via
transcription factor Nrf2 augments vesicular stomatitis virus
D51 (VSVD51) replication and sensitizes cancer cells to viral
oncolysis. Activation of Nrf2 signaling by the antioxidant com-
pound sulforaphane (SFN) leads to enhanced VSVD51 spread
in OV-resistant cancer cells and improves the therapeutic
outcome in different murine syngeneic and xenograft tumor
models. Chemoresistant A549 lung cancer cells that display
constitutive dominant hyperactivation of Nrf2 signaling are
particularly vulnerable to VSVD51 oncolysis. Mechanistically,
enhanced Nrf2 signaling stimulated viral replication in cancer
cells and disrupted the type I IFN response via increased auto-
phagy. This study reveals a previously unappreciated role for
Nrf2 in the regulation of autophagy and the innate antiviral
response that complements the therapeutic potential of VSV-
directed oncolysis against multiple types of OV-resistant or
chemoresistant cancer.
INTRODUCTION
Oncolytic virotherapy is an innovative form of experimental cancer
therapy that uses different virus platforms as self-amplifying bio-
therapeutics to selectively infect, multiply, and kill cancer cells while
sparing healthy tissues.1–4 The therapeutic potential of oncolytic vi-
ruses (OVs) is highlighted by the approval of oncolytic recombinant
herpes virus talimogene laherparepvec (T-VEC) to treat malignant
melanoma in the United States.5 However, variability in the clinical
response to OV-based therapies and engagement of the adaptive im-
mune response against viral rather than tumor antigens are critical
roadblocks to the large-scale implementation of OVs against multiple
types of cancer.6 In addition, nearly one-third of cancer cell lines and
many primary tumors maintain a residual innate immune response
that renders cells resistant to infection and virus-mediated cell
killing.6 To circumvent these issues, several strategies that combine
OVs with chemical agents or engineering recombinant viruses with
enhanced antitumoral activity have been investigated.7–14
Vesicular stomatitis virus (VSV), an enveloped negative-sense RNA
virus from the Rhabdoviridae family, is a prototypical OV that has
demonstrated potent oncolytic activity in preclinical models and is be-
ing evaluated in clinical trials.6,15,16 Different genetic variants of VSV
have been engineered to preferentially target tumors without compro-
mising healthy cells. For example, VSVD51 contains a deletion at
methionine 51 in the matrix protein that improves its tumor speciﬁcity
and impairs its replication in normal cells that have functional antiviral
defenses.17,18 In previous studies,we demonstrated the synergistic effect
of different agents, including histone deacetylase inhibitors (HDIs), as
chemical switches to dampen the type I interferon (IFN) response and
to increase VSVD51 replication within resistant malignancies.10,12 We
also showed that pharmacologic disruption of the BCL-2-Beclin-1 in-
teractions facilitated autophagy and increased the VSVD51-mediated
cytolytic effect in chronic lymphocytic leukemia cells.19
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcriptional
regulator involved in the maintenance of redox homeostasis through
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Figure 1. Sulforaphane Enhances VSVD51-Mediated Oncolytic Activity in Resistant PC-3 Cells
PC-3 cells were pretreated for 24 hr with increasing concentrations of sulforaphane (SFN) and were subsequently infected with VSVD51-GFP (MOI 1). (A and B) Infectivity was
determinedbyfluorescentmicroscopy (A)or quantifiedbyflowcytometry (B)at the indicated times. (C)Viral replicationwasassessedbyplaqueassay. (D)Cell survivalwas imaged
by light microscopy 72 hr following VSVD51 challenge. (E and F) The percentage of viable (E) and apoptotic cells (F) was assessed using an annexin-V/7AAD staining by flow
cytometry at the indicated times. (A–F) Data are the means ± SEM from two experiments performed in triplicate. (G) The correlation between the percentage of VSVD51-GFP+
(legend continued on next page)
Molecular Therapy
2 Molecular Therapy Vol. 25 No 8 August 2017
Please cite this article in press as: Olagnier et al., Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven
Suppression of Antiviral Immunity, Molecular Therapy (2017), http://dx.doi.org/10.1016/j.ymthe.2017.04.022
the control of basal and induced expression of an array of antioxidant
enzymes.20 Under homeostatic conditions, Nrf2 binds to Kelch-like
ECH-associated protein 1 (Keap1), a substrate adaptor protein for
the E3 ubiquitin ligase complex formed by CUL3 and RBX1 that
targets Nrf2 for ubiquitination and degradation by the proteasome.
During endogenous or exogenous stresses caused by either reactive
oxygen species (ROS) or electrophilic chemicals, cysteine residues
in Keap1 aremodiﬁed, thereby inactivating its substrate adaptor func-
tion and disrupting the cycle of Nrf2 degradation.21 This results in
Nrf2 stabilization, its nuclear translocation, and the transcriptional
upregulation of a multitude of antioxidant response element
(ARE)-bearing genes that alleviate the stress response.20
Induction of Nrf2 signaling by thiol-reactive small molecules has
demonstrated protective efﬁcacy in chemoprevention tumor models
and clinical trials.22 As an example, sulforaphane (SFN), an aliphatic
isothiocyanate with anti-inﬂammatory properties known to activate
Nrf2,23,24 has shown efﬁcacy in men with high-grade prostatic intra-
epithelial neoplasia25 and is being tested as a therapy for recurrent
prostate cancer in phase II clinical trials.26–28 Conversely, genetic
analyses of human tumors have indicated that mutations and
epigenetic modiﬁcations affecting the regulation of Nrf2 may cause
resistance to chemotherapy through constitutive dominant hyperac-
tivation of Nrf2 signaling.29–31
In this study, we demonstrate that the transcription factor Nrf2 is
required to direct VSVD51 replication and oncolysis in some cancer
cells. A combinatorial treatment of VSVD51 and the Nrf2 inducer
SFN markedly increases viral replication and oncolysis in different
cancer cell lines both in vitro and in vivo. We further show that
Nrf2-constitutively active chemoresistant lung cancer (A549) cells
are particularly vulnerable to VSVD51-driven oncolysis and do not
require SFN treatment. Mechanistically, we show that either genetic
or chemical induction of Nrf2 signaling suppressed the type I IFN
response via increased autophagy. By transiently silencing Nrf2 and
Atg7, we demonstrate that Nrf2-mediated autophagy is critical for
VSVD51 replication in chemoresistant A549 cells and bone osteosar-
coma (U-2 OS) cells. Altogether, our ﬁndings highlight a previously
unappreciated role for Nrf2 in the control of antiviral innate immu-
nity and VSVD51 oncolysis.
RESULTS
SFN Enhances VSVD51 Replication and Oncolysis in PC-3 Cells
The capacity of SFN to augment VSVD51 replication was initially
evaluated in human prostate cancer (PC-3) cells that display signiﬁ-
cant resistance to VSVD51-mediated cell killing.10,12 SFN potentiated
VSVD51-GFP infectivity in a dose-dependent manner, as measured
by ﬂow cytometry analysis of VSVD51-GFP+ cells (Figures 1A and
1B). The number of VSVD51-infected cells increased from 4.2%
with VSVD51 alone to 55.3% in combination with SFN (20 mM) at
48 hr (***p < 0.001) (Figure 1B). Similarly, the titer of VSVD51
released from infected PC-3 cells increased approximately 2 logs
with SFN pretreatment (Figure 1C). In other human and murine
cancer cell lines (DU145 and TS/A), the combination of SFN and
VSVD51 also signiﬁcantly increased infection when compared with
VSVD51 alone (Figure S1).
To evaluate the cytotoxic effect of the VSVD51+SFN combination,
PC-3 tumor cells were pretreated with increasing doses of SFN and
subsequently infected with VSVD51 and analyzed for viability and
apoptosis at various times post-infection (p.i.) by microscopy (Fig-
ure 1D) and ﬂow cytometry (Figures 1E and 1F). Enhanced cell killing
was elicited by the combinatorial treatment, but not by individual treat-
ment, based on the proportion of annexin-V+ cells and cell viability
(Figure 1D; Figures S2A–S2C). The 24 hr point illustrates the number
of infected GFP+ cells and a low level of cell death; by 48 hr, the overall
number of GFP+ cells remained similar, but virus-induced cell death
was readily detected (Figures 1B–1F). The VSVD51+SFN combination
signiﬁcantly enhanced VSVD51-mediated PC-3 cell killing (17.2%
annexin-V+ cells in VSVD51 versus 78.33% in VSVD51+SFN)
(***p < 0.001) and decreased cell viability (80.7% in VSVD51 versus
17.2% in VSVD51+SFN) (***p < 0.001) at 72 hr p.i. (Figures 1E and
1F). A strong statistical correlation between percentage of annexin-V+
cells at 48 hr p.i. and VSVD51 infectivity at 24 hr was conﬁrmed by
the nonparametric Spearman test (r = 0.7774; p < 0.0001; n = 33) (Fig-
ure 1G). In contrast, SFNonly slightly increasedVSVD51 infectivity and
did not affect VSVD51 oncolysis in human non-transformed MRC-5
ﬁbroblasts compared to PC-3 cells (Figures S3A and S3B).
To assess the involvement of the mitochondrial pathway in mediating
VSVD51-induced cell death, PC-3 cells pretreated with SFN and
infected with VSVD51 were stained with MitoSOX, a probe speciﬁc
for mitochondria-derived ROS. The levels of mitochondrial ROS
release were statistically associated with the number of annexin-V+
cells at 48 hr p.i. (r = 0.924; p < 0.0001; n = 36) (Figure 1H). Further-
more, and consistent with the release of ROS at the mitochondria,
downstream caspases—caspase-3 and caspase-7—were activated
with the combinatorial treatment, leading to poly (ADP-ribose)
polymerase (PARP) cleavage (Figure 1I) and indicating that SFN
enhanced VSVD51 replication, which preceded mitochondrial-
dependent apoptosis in PC-3 cells.
SFN-VSVD51 Combination Therapy Delays Tumor Progression
and Improves Survival
The therapeutic effect of combined VSVD51+SFN treatment was next
evaluated in vivo using both syngeneic and xenograft mouse tumor
cells at 24 hr and the percentage of apoptotic annexin-V+ cells at 48 hr was calculated in PC-3 cells using a Spearman test (n = 33). (H) The same statistical test was used to
calculate the correlation between thepercentageof apoptotic annexin-V+ cells and the percentageofMitoSOX+ cells at 48 hr after infection (n= 36). (I) PC-3 cellswere pretreated
for 24 hr with SFN (20 mM) and challenged with VSVD51-GFP (MOI 1) for 48 hr. Whole-cell extracts (WCEs) were analyzed by immunoblotting for cleaved caspase-3, cleaved
caspase-7 (high and low exposure), cleaved PARP, VSVD51-GFP, and b-actin. Results are from a representative experiment; all immunoblots are from the same samples.
www.moleculartherapy.org
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models. First, using a syngeneic immunocompetent mice tumor
model engrafted subcutaneously (s.c.) with the murine breast cancer
cell line TS/A, we demonstrate that murine breast tumor allografts
were also signiﬁcantly sensitized to intratumoral delivery of oncolytic
VSVD51 (2  107 plaque-forming units [PFU]/injection) following
intraperitoneal (i.p.) administration of SFN (10 mg/kg). Tumors
treated with VSVD51+SFN displayed a 4-fold decrease in tumor vol-
ume, compared with animals receiving monotherapies (***p < 0.001
between VSVD51 and VSVD51+SFN) (Figure 2A); furthermore,
combination treatment had a signiﬁcant effect in prolonging survival
(median survival in days: not treated [NT] = 34; SFN = 34; VSVD51 =
36; VSVD51+SFN = 50). The log rank test indicates that the com-
bined treatment signiﬁcantly prolonged survival over virus alone
(**p = 0.0064) or SFN alone (***p = 0.0002). Interestingly, 43%
(3 of 7) of the mice were cured as a result of VSVD51+SFN treatment
(Figure 2B), without signiﬁcant weight loss (Figure 2C). In athymic
nude mice engrafted s.c. with human PC-3 cells, a delay in tumor pro-
gression (***p < 0.001 between VSVD51 and VSVD51+SFN) and
prolonged survival was also observed with co-administration of
VSVD51+SFN (Figures 2D and 2E), without weight loss (Figure 2F)
(median survival in days: NT = 27; SFN = 27; VSVD51 = 36;
VSVD51+SFN = 48). SFN treatment alone appeared to enhance tu-
mor growth, in agreement with the cytoprotective role of Nrf2 activa-
tion. The log rank test also indicates that the combined treatment
signiﬁcantly prolonged survival over no treatment (***p = 0.0005)
and SFN-alone treatment (**p = 0.0036) and is approaching statistical
signiﬁcance over virus-alone treatment (p = 0.0565). Collectively,
these data demonstrate that the VSVD51+SFN combination in vivo
is signiﬁcantly more effective than monotherapy.
VSVD51 Relies on Nrf2 to Replicate and Drive Oncolysis
We next sought to investigate the mechanisms of SFN-mediated
enhancement of VSVD51 replication in PC-3 cells by examining
the activation of Nrf2 following SFN exposure by Phosﬂow
Figure 2. VSVD51 and Sulforaphane Combinatorial
Treatment Reduces Tumor Progression and
Prolongs Survival in Mouse Syngeneic and
Xenograft Tumor Models
(A–C) A murine TS/A (3  105 cells) subcutaneous model
was established in immunocompetent BALB/c mice
(n = 7). After 7 days, when tumors became palpable, they
were injected with 2  107 PFU of the VSVD51-GFP at
day 0 and day 4. Sulforaphane (SFN) at 10 mg/kg was
administered i.p. 1 day before the first VSVD51 injection
and then days 1, 4, and 6 following the first VSVD51
administration. (A) Tumor growth was monitored using
caliper measurements at the indicated times, and average
tumor volumes (n = 7) are shown. To account for variable
tumor size at the beginning of the experiment, tumor vol-
ume was normalized to its initial volume on day 0 and
presented as percentage. Error bars correspond to the
SEM. ***p < 0.001 by two-way ANOVA. (B) Cumulative
survival rate (n = 7) was monitored over time. The log rank
test indicates that the combined treatment is significantly
prolonged over virus alone (**p = 0.0064) or SFN alone
(***p = 0.0002). (C) The cytotoxicity of each treatment was
assessed by monitoring mouse body weight. Error bars
correspond to the SEM (n = 7). (D–F) Human PC-3 cells
were established in athymic male nude mice. Four weeks
later, animals were treated by intratumoral injection with
VSVD51 (2  107 PFU/dose) on days 0, 3, 6, 9, and 12
and then treated intraperitoneally with SFN (10 mg/kg)
every day from day 1 to day 10. (D) Tumor volume was
monitored for each group, and average tumor volumes
were normalized as shown (n = 7). To account for variable
tumor size at the beginning of the experiment, tumor vol-
ume was normalized to its initial volume on day 0 and
presented as percentage. Error bars correspond to the
SEM. ***p < 0.001 by two-way ANOVA. (E) Survival rate
(n = 7) wasmonitored over time. The log rank test indicates
that the combined treatment is significantly prolonged over
non-treated (***p = 0.0005) and SFN alone (**p = 0.0036).
(F) The cytotoxicity of each treatment was assessed by
monitoring mouse body weight (n = 7).
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Figure 3. VSVD51 Replication Relies on Nrf2 and HO-1
(A) Intracellular levels of phosphorylated Nrf2 were detected by Phosflow in HEK293T stimulated for 18 hr with increasing doses of SFN. (B) HEK293T cells were pretreated for
24 hr with increasing doses of SFN, and the ARE promoter activity was assessed using a luciferase assay. (C) High-throughput analysis of gene expression was evaluated by
qPCR BioMark analysis on PC-3 cells pretreated with SFN (20 mM) for 24 hr and subsequently infected with VSVD51-GFP (MOI 1) for 24 hr. Gene expression levels were
calculated using the DDCt method, and the gene-wise standardized expression (Z score) was generated for each gene. The scale represents Z score values, with red
(legend continued on next page)
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cytometry. Increased levels of phosphorylated Nrf2 were observed as
the dose of SFN increased (Figure 3A), and using an ARE promoter-
luciferase assay, enhanced ARE promoter activity was observed with
increasing SFN concentration (Figure 3B). Using high-throughput
qRT-PCR analysis to examine the Nrf2-dependent gene expression
proﬁle in PC-3 cells, we observed the induction of a cross section
of Nrf2-regulated genes following SFN treatment, independent of
VSVD51 infection (Figure 3C). Hmox-1 was the most highly induced
Nrf2-stimulated gene after SFN treatment, as shown by an 3-fold
increase in mRNA expression level in both the presence and absence
of VSVD51 (***p < 0.001) (Figure 3C). Another known inducer of
Nrf2, diethyl maleate (DEM), increased ARE promoter activity and
enhanced VSVD51 infectivity in a dose-dependent manner, with a
4-fold increase in ARE activity at 100 mM (***p < 0.001) (Fig-
ure S4A); as with SFN, DEM enhanced VSVD51 infectivity in
resistant PC-3 cells, as measured by ﬂow cytometry analysis of
VSVD51-GFP+ cells (Figure S4B).
SFN was previously shown to stimulate Nrf2 partly through intracel-
lular ROS accumulation.32,33 To determine whether Nrf2 induction
and VSVD51 replication were dependent on increased ROS release
following SFN treatment, an oxidant-sensitive ﬂuorescent detection
probe, CM-H2DCFDA, was used to monitor ROS formation by ﬂow
cytometry. H2O2 and pyocyanin were used as positive controls to vali-
date the oxidation of the probe and the detection of ROS accumulation.
Increased ROS production was not observed at 4 hr or at 24 hr after
PC-3 cell stimulationwith SFN (Figure S5A). In addition, pretreatment
of cells with the ROS scavenger N-acetyl-L-cysteine (L-NAC) did
not interfere with the SFN-enhanced ARE-Luc promotor activity or
VSVD51 infectivity, while L-NACwas effective at reducing ROS accu-
mulation following treatment with pyocyanin, a potent ROS inducer
(Figures S5B–S5D). These data indicate that induction of Nrf2 using
electrophilic chemical agents potentiates VSVD51-infectivity indepen-
dently of intracellular ROS accumulation in PC-3 cells.
To determine whether SFN-induced VSVD51 replication required
the activation of Nrf2 and the downstream antioxidant response,
we examined VSVD51 replication in murine embryonic ﬁbroblasts
(MEFs) deﬁcient for Nrf2 (Nrf2/), infected with VSVD51 in the
presence or absence of SFN. Cells lacking Nrf2 had signiﬁcantly lower
infectivity rates when compared to wild-type (WT) MEFs after SFN
treatment (**p < 0.01) (Figure 3D). To validate that SFN-induced
VSVD51 infectivity relies on Nrf2, MEFs deﬁcient for Keap1
(Keap1/) were also examined. VSVD51 infectivity in Keap1/
MEFs had similar levels of infection to WT MEFs treated with SFN
(Figure 3D).34 However, VSVD51 infectivity in Keap1/ MEFs
was enhanced by SFN treatment, suggesting that SFN has additional
effects that are independent of the Nrf2/Keap1 axis.
The human A549 cell line possesses a point mutation in Keap1 that
abolishes its capacity to repress Nrf2, leading to constitutive Nrf2-
mediated gene expression.31 Heme oxygenase-1 (HO-1) is one of
the well-characterized Nrf2-regulated genes shown to modulate
subcellular distribution and activation of Nrf2 to enhance antioxi-
dant defenses.35 To evaluate the importance of this axis in VSVD51
replication, chemoresistant A549 cells were transiently knocked
down for Nrf2 or HO-1 using a small-interfering RNA (siRNA)
approach (Figure 3E). A549 cells endogenously express high levels
of HO-1 and were highly susceptible to VSVD51 infection (80%
infection with VSVD51 at MOI 0.01) (Figures 3E and 3F). A549
cells knocked down for Nrf2 or HO-1 had nearly 4-fold fewer
VSVD51-GFP+ cells (***p < 0.001) (Figure 3F) and a more than
10-fold decrease in virus titers compared to the siRNA control-
treated cells (***p < 0.001) (Figure 3G). Nrf2 or HO-1 knockdown
signiﬁcantly reduced VSVD51-mediated cell killing, as shown by
a 2 to 3-fold decrease in the number of annexin-V+ apoptotic
cells (Figure 3H). The knockdown of Nrf2 also signiﬁcantly
affected the levels of VSVD51 infection in both the presence and
the absence of SFN in A549 cells (Figure 3I). However, as observed
in the Keap1/ MEF cells, VSVD51 infectivity was slightly
enhanced by SFN treatment, suggesting an Nrf2-independent effect
of SFN in cells constitutively active for Nrf2. Finally, to broaden
our observation that Nrf2 facilitates VSVD51 replication in cancer
cells, U-2 OS cells were transiently knockdown for Nrf2 using
an siRNA approach (Figure 3J). The lack of Nrf2 facilitated
VSVD51 infection in U-2 OS cells, as demonstrated by a signiﬁcant
decrease in viral protein expression and infectivity (***p < 0.001)
(Figures 3J and 3K). Collectively, these experiments indicate that
VSVD51 relies on Nrf2 to replicate and drive oncolysis in A549
cells and U-2 OS cells.
VSVD51 Replication Is Dependent on Nrf2-Mediated Autophagy
Previous studies demonstrated that SFN can trigger autophagy in
cancer cells36 and that autophagy increases VSVD51 replication.12,37
The ability of SFN to induce autophagy was examined by evaluating
the levels of two autophagy biomarkers: the microtubule-associated
showing upregulation and blue showing downregulation in gene expression. Data are representative of three independent experiments. Each box of the heatmap represents
one experiment. (D) WT, Nrf2/, and Keap1/MEF cells were pretreated for 18 hr with SFN (10 mM) and subsequently challenged with VSVD51-GFP (MOI 0.1). Infectivity
was quantified by flow cytometry 24 hr post-infection. Data are the means ± SEM of one representative experiment performed in triplicate. The experiment was repeated
twice with the same trend. (E–H) A549 cells were transfected with control, Nrf2, or HO-1 siRNA and 48 hr later were infected with VSVD51-GFP (MOI 0.01) for an extra 24 or
48 hr. (E) Knockdown efficiency was assessed by immunoblotting. Viral infectivity and replication were determined by microscopy (F) and plaque assay (G) at 24 hr post-
infection, respectively. (H) Apoptosis was determined by flow cytometry 48 hr post-infection. Data are the means ± SEM of one representative experiment performed in
triplicate. Experiment was repeated twice with the same trend. (I) A549 cells were transfected with control or Nrf2 siRNA and 48 hr later were infected with VSVD51-GFP (MOI
0.01) in the presence or absence of SFN (7.5 mM) for an extra 24 hr. Viral infectivity was determined by flow cytometry. Data are the means ± SEM of two independent
experiments performed in duplicate. (J) U-2 OS cells were transfected with control or Nrf2 siRNA and 48 hr later were infected with VSVD51-GFP (MOI 0.001). Whole-cell
extracts were also analyzed by immunoblotting for Nrf2, VSV proteins, and b-actin. (K) Viral infectivity was determined by flow cytometry 24 hr post-infection. Data are the
means ± SEM of three independent experiments.
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Figure 4. Sulforaphane-Enhanced VSVD51 Replication and Oncolysis Is Dependent on Nrf2-Dependent Autophagy
(A) Immunofluorescence analysis of U-2 OS cells was conducted to detect changes in the levels of p62 and LC3-II in response to a 24 hr treatment with SFN (20 mM). (B) PC-3
cells were pretreated with SFN (20 mM) for 24 hr and were subsequently infected with VSVD51-GFP (MOI 1). Whole-cell extracts were analyzed by immunoblotting for LC3B,
(legend continued on next page)
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light chain 3 protein (LC3) isoform II and the autophagic cargo pro-
tein p62/SQSTM1. Immunoﬂuorescence showed increased levels of
both p62 and LC3-II and further revealed that these two proteins
co-localize in the cytoplasm of SFN-treated U-2 OS cells (Figure 4A).
The same was observed in PC-3 cells; a dose optimization established
that exposure to SFN caused an increase in the lipidated form of LC3-
II (Figure 4B), and PC-3 cells treated with the VSVD51+SFN combi-
nation generated more lipidated LC3-II than cells infected with
VSVD51 alone (Figure 4B). Furthermore, when 3-methyladenine
(3-MeA), a general phosphatidylinositol 3-kinase (PI3K) and auto-
phagy inhibitor, was used in combination with SFN, a 3-fold reduc-
tion in the number of infected cells was observed (**p < 0.01) (Fig-
ure 4C), suggesting the possible involvement of autophagy in
driving SFN-increased VSVD51 infectivity in PC-3 cells.
To unequivocally demonstrate the involvement of autophagy in
SFN-mediated VSVD51 replication and infectivity, MEFs deﬁcient
for Atg5, an essential autophagic protein responsible for autophago-
somal elongation, were used.Atg5/MEFs showed no signiﬁcant in-
crease in VSVD51-GFP+ cells or virus titers when treated with SFN,
whereas the WT MEFs had approximately a 10-fold increase in the
number of VSVD51-GFP+ cells and 50-fold higher virus titers
compared to Atg5/ cells (Figures 4D and 4E). A similar increase
in LC3-II accumulation was observed in WT MEFs with the
VSVD51+SFN combination. In contrast, Atg5/ MEFs showed no
VSVD51 protein expression and a marked reduction in increased
levels of LC3-II (Figure 4F), indicating that SFN-stimulated auto-
phagy facilitates VSVD51 replication.
Because both Nrf2 activation and autophagy depend on stress induc-
tion, we investigated whether Nrf2 activation regulates autophagy.
Using siRNA-mediated silencing, Nrf2 expression was knocked
down in A549 cells, leading to abrogation of LC3-II expression
upon SFN treatment and suggesting that autophagy is partly depen-
dent on Nrf2 expression in these cells (Figure 4G). These results agree
with a report showing that Nrf2 regulates the gene expression of a
number of proteins involved in the autophagy process.38 The same
was observed upon HO-1 knockdown in A549 cells, which sup-
pressed SFN-induced increase in LC3-II (Figure 4H). The result
was also observed in siRNA Nrf2 (siNrf2)-transfected U-2 OS cells,
because no increase in LC3-II or p62 was detected in the absence of
Nrf2 following SFN stimulation (Figure 4I). Collectively, these results
demonstrate that VSVD51 replication is dependent on Nrf2/HO-1-
mediated autophagy in different cancer cell lines.
SFN Dampens the Innate Antiviral Response
To investigate whether SFN modulates the antiviral response,
HEK293T cells were transfected with the IFN-stimulated response
element (ISRE)-luciferase reporter plasmid (Luc) and infected with
VSVD51 in the presence or absence of increasing doses of SFN.
SFN inhibited VSVD51-mediated induction of ISRE-Luc activity in
a dose-dependent manner (Figure 5A). Using a high-throughput
qPCR approach, we assessed the levels of IFN-stimulated genes
(ISGs), including Ccl5, Cxcl10, Tmem173, Ddx58, and Irf7, which
were all highly induced by VSV infection, whereas SFN treatment in-
hibited ISG expression; VSVD51-induced Ifnb1 and Il-29 mRNA
were drastically inhibited by SFN by more than 50 and 500 times,
respectively (Figure 5B). Other ISGs, such as Iﬁtm1, Rsad2, Mx1,
Isg15, Isg56, and Oasl, were also inhibited in SFN-treated cells (Fig-
ure 5B). Phosphorylation of IRF3 and STAT1 and the subsequent
expression of ISGs such as STAT1 and STING were drastically in-
hibited at the protein level by the presence of SFN (Figure 5C). The
decreased antiviral response also correlated with induced expression
of HO-1 (Figure 5C), illustrating that increased VSVD51 infection
correlates with an Nrf2-mediated inhibition of the host antiviral
response. IRF3 is a critical transcription factor required for type I
IFNs and ISG expression;39 because IRF3 phosphorylation was
affected by SFN treatment, we examined whether SFN also prevented
IRF3 nuclear translocation and binding activity following VSVD51
infection. SFN interfered with IRF3 nuclear relocation, as denoted
by the absence of IRF3 in nuclei of VSVD51+SFN-stimulated cells
(Figure 5D). Nuclear translocation of Nrf2 was also observed in the
same conditions (Figure 5D). As a result of IRF3 nuclear translocation
impairment in SFN-treated cells, IRF3 failed to bind to its cognate
binding site following SFN stimulation (Figure S6).
Nrf2-Mediated Autophagy Dampens VSVD51-Induced Innate
Antiviral Response
Using Sendai virus as a potent stimulator of the antiviral response,
Nrf2 overexpression inhibited virus-mediated ISRE-Luc activity in a
dose-dependent manner (Figure 6A), and knockdown of Nrf2 in
A549 cells led to higher levels of P-STAT1, STAT1, and RIG-I in
response to VSVD51 (Figure 6B). Increased expression of these anti-
viral markers correlated with a profound inhibition of the autophagic
ﬂux and a decreased capacity for VSVD51 to replicate in A549 cells
silenced for Nrf2 (Figure 6B).
Our data have shown that VSVD51 replication also relies on the Nrf2-
regulated gene HO-1. Using the observation that upregulation of
autophagy increases VSVD51 replication, we investigated whether
VSV proteins, ATG5, and b-actin. Results are from a representative experiment; all immunoblots are from the same samples. (C) PC-3 cells were pretreated with SFN (20 mM)
in the presence or absence of the PI3K/autophagy inhibitor 3-MeA (10mM) for 24 hr. Cells were subsequently infected with VSVD51-GFP (MOI 1). Infectivity was quantified by
flow cytometry at 24 hr post-infection. Data are themeans ±SEM from three independent experiments. (D–F)WTAtg5 and Atg5/MEFswere stimulated overnight with SFN
(7.5 mM) before challenge with VSVD51 (MOI 0.01). Viral infectivity was determined by flow cytometry (D) and viral replication by plaque assay (E). (F) Whole-cell extracts were
analyzed by immunoblotting for LC3B, VSV proteins, ATG5, and b-actin. (G and H) A549 cells were transfected with control, Nrf2, or HO-1 siRNA and 48 hr later were treated
with SFN (15 mM) for an extra 24 hr. Whole-cell extracts were analyzed by immunoblotting for Nrf2, HO-1, LC3, and b-actin. (I) Immunofluorescence analysis of U-2 OS cells
was conducted to detect the changes in the levels of p62 and LC3-II in response to a 24 hr treatment with SFN (20 mM) in the presence of Nrf2 (siCtrl) or absence of Nrf2
(siNrf2).
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the dampening of the antiviral response was also related to HO-1-
mediated autophagy. Increased expression of HO-1 in HEK293T cells
inhibited Sendai virus-mediated ISRE activity in a dose-dependent
manner (Figure 6C). Similar to the observations in Nrf2-silenced
cells, HO-1 knockdown resulted in higher levels of the antiviral effec-
tors P-STAT1, STAT1, and RIG-I following VSVD51 infection,
compared to HO-1-sufﬁcient cells (Figure 6D). Stimulation of the
antiviral response correlated with decreased VSVD51 replication
and expression of the autophagy marker LC3-II (Figure 6D). Alto-
gether, genetic inhibition of both Nrf2 and HO-1 limited autophagy
in A549 cells and led to increased antiviral immunity, which further
limited VSVD51 replication.
Previously, Jounai et al.37 demonstrated, using Atg5 and Atg7
knockout (KO) MEFs, that autophagy increased virus replication by
suppressing the innate antiviral response. To validate this relation-
Figure 5. Sulforaphane Dampens the Innate Antiviral
Response
(A) HEK293T cells were pretreated for 24 hr with
increasing doses of SFN (1–20 mM), and the ISRE pro-
moter activity was assessed using a luciferase assay in the
presence or absence of VSVD51 (MOI 0.01). (B) PC-3
cells were pretreated with sulforaphane (SFN) (20 mM) for
24 hr and were subsequently infected with VSVD51-GFP
(MOI 1). Antiviral and inflammatory gene expression levels
were assessed by high-throughput qPCR. (C) PC-3 cells
were pretreated for 24 hr with SFN (20 mM) and subse-
quently challenged with VSVD51-GFP (MOI 1) for 24 hr.
Whole-cell extracts were analyzed for P-IRF3, IRF3,
P-STAT1, STAT1, STING, HO-1, LC3, VSV proteins, and
b-actin by immunoblotting. (D) PC-3 cells were pretreated
for 24 hr with SFN (20 mM) and subsequently challenged
with VSVD51-GFP (MOI 1) for 8 hr. Translocation of IRF3
and Nrf2 from cytoplasm to nucleus was investigated by
immunoblotting in cytoplasmic and nuclear fractions at the
same time. The experiment was repeated twice.
ship, Atg7 expression was silenced in A549 cells;
cells knocked down for Atg7 had 2-fold fewer
VSVD51-GFP+ cells (***p < 0.001) (Figure 6E;
Figure S7A) and an 1 log decrease in virus
titers compared to the siRNA control-treated
cells (*p < 0.05) (Figure S7B). Atg7 knockdown
resulted in a marked increase in P-STAT1 and
RIG-I expression that correlated with >90%
inhibition of VSVD51 protein expression (Fig-
ure 6F), thus demonstrating that inhibition of
autophagy also increased the antiviral response
in A549 cells.
To further evaluate the effect of autophagy on
VSVD51 replication and antiviral responses,
U-2 OS cells were silenced for Nrf2 using siRNA.
Cells lacking Nrf2 had reduced VSVD51 infec-
tivity and replication (Figures 6G and 6H), which correlated with a
reduction in LC3-II expression and increased STAT1 signaling, as de-
noted by the elevated level of STAT1 phosphorylation (Figure 6H).
Collectively, our data demonstrate that induction of Nrf2 signaling
drives autophagy to decrease innate antiviral responses and potentiate
VSVD51 replication and oncolytic activity in different cancer cell
models (Figure 7).
DISCUSSION
Many tumor cell lines and primary cancer specimens exhibit resis-
tance to infection by OVs, partly because of persistent antiviral
immunity.6 In the effort to increase the efﬁcacy of experimental
oncolytic virotherapies, we and others have explored strategies to
potentiate viral oncolysis in resistant cancer cells by combining
OVs with small molecules that enhance virus replication and cell
killing.7–14 In the present study, we demonstrate that the restriction
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Figure 6. Nrf2-Induced Autophagy Curtails Antiviral Innate Immunity
(A) 6 hr following transfection with increasing doses of an Nrf2 overexpression plasmid, HEK293T cells were infected with Sendai virus (SeV) (40 hemagglutinin [HA]/mL) for
18 hr and ISRE promoter activity was assessed by a luciferase reporter assay. (B) A549 cells were transfected with control or Nrf2 siRNA and 48 hr later were challenged with
VSVD51-GFP (MOI 0.01) for an extra day. Whole-cell extracts were analyzed for Nrf2, VSV-GFP, LC3, P-STAT1, STAT1, RIG-I, and b-actin by immunoblotting. (C) 6 hr
following transfection with increasing doses of an HO-1 overexpression plasmid, HEK293T cells were infected with SeV (40 HA/mL) for 18 hr and ISRE promoter activity was
assessed by a luciferase reporter assay. (D) A549 cells were transfected with control or HO-1 siRNA and 48 hr later were challenged with VSVD51-GFP (MOI 0.01) for an extra
day. Whole-cell extracts were analyzed for HO-1, VSV-GFP, LC3, P-STAT1, STAT1, RIG-I, and b-actin by immunoblotting. (E and F) A549 cells were transfected with control
or Atg7 siRNA and 48 hr later were challenged with VSVD51-GFP (MOI 0.01) for an extra day. (E) VSVD51 infection was determined by flow cytometry. Data are the means ±
SEM of three independent experiments. (F) Whole-cell extracts were analyzed for VSV proteins, RIG-I, P-STAT1, STAT1, and b-actin by immunoblotting. (G and H) U-2 OS
cells were transfected with control or Nrf2 siRNA and 48 hr later were infected with VSVD51-GFP (MOI 0.001). (G) Viral infectivity was determined by flow cytometry 24 hr
post-infection and observed using a fluorescent microscope. Data are the means ± SEM of three independent experiments. (H) Whole-cell extracts were also analyzed by
immunoblotting for Nrf2, VSV proteins, LC3, P-STAT1, and b-actin.
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to VSVD51 oncolysis can be overcome by manipulation of the oxida-
tive stress response using the antioxidant compound SFN as an
inducer of Nrf2 antioxidant activity. We demonstrated that (1) SFN
selectively increased VSVD51 infectivity and cell death in cancer cells,
(2) the combination of SFN and VSVD51 decreased tumor volume
and increased survival in vivo, (3) VSVD51 replication was dependent
on activation of the Nrf2 pathway, (4) VSVD51 replication relied on
Nrf2/HO-1-mediated autophagy, and (5) activation of autophagy
through the Nrf2/HO-1 axis suppressed the innate antiviral response
by inhibiting IRF3 activity.
SFN is the major isothiocyanate derived from broccoli,40 produced by
the enzymatic hydrolysis of glucosinolates that are present in crucif-
erous plants, including broccoli sprouts.41 Glucoraphanin, the pre-
dominant glucosinolate, is biologically inactive but is transformed
into SFN by the enzymatic activity of myrosinase. SFN is rapidly ab-
sorbed in the blood and possesses antioxidant, anti-inﬂammatory,
and cytoprotective activities. The anticancer potential of SFN has
been observed in cancer cells, in carcinogen-induced and genetic an-
imal cancer models, and in xenograft models of cancer.42,43 Further-
more, the combination of SFNwith existing cancer chemotherapeutics
was shown to increase the cytotoxic effect in vitro,42 thus suggesting a
potential therapeutic beneﬁt in the clinical setting.
SFN treatment stimulated Nrf2 expression and dampened the
antiviral innate immune response via upregulation of autophagy,
thus facilitating OV-mediated cell killing both in vitro and in vivo.
Mechanistically, SFN prevented IRF3 nuclear translocation and
binding to its cognate binding element, thus preventing downstream
STAT1 activation and the induction of ISGs. In A549 cells, the anti-
viral response to VSVD51 was suppressed because of the constitu-
tive activation of Nrf2; antiviral immunity was stimulated only
when Nrf2, HO-1, or Atg7 was selectively silenced using siRNA,
thus reﬂecting the importance of the Nrf2 axis and the autophagy
Figure 7. Nrf2-Dependent Autophagy Decreases the Innate Antiviral Response to Augment VSVD51 Replication and Oncolytic Activity in Cancer Cells
(A) Under homeostatic conditions, Nrf2 is sequestered in the cytoplasm by Keap1, a substrate adaptor protein for a E3 ubiquitin ligase complex that targets Nrf2 for
ubiquitination and degradation by the proteasome. (B) Upon stimulation with sulforaphane (SFN), cysteine residues in Keap1 are modified, thereby inactivating its substrate
adaptor function and disrupting the cycle of Nrf2 degradation. This results in Nrf2 stabilization, its nuclear translocation, and the transcriptional upregulation of a multitude of
genes bearing antioxidant response element (ARE) in their promoter, including HO-1. (C and D) Increased Nrf2 signaling induces autophagy (C), which negatively regulates
VSVD51-induced immune response (D) by disrupting RIG-I-MAVS interactions. (E and F) Suppression of the antiviral response facilitates VSVD51 replication (E) and oncolysis
(F) in cancer cells.
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pathway in regulating VSVD51-induced immune response. These
observations are in agreement with Jounai et al.,37 who demon-
strated that the Atg5-Atg12 autophagy complex negatively regu-
lated IRF3 signaling by preventing the association between RIG-I
and MAVS.
Furthermore, Nrf2 has been shown to regulate the expression
of a number of proteins involved in macroautophagy38 as well as
ATG3, an E2-like enzyme required for the conjugation of LC3B
to phosphatidylethanolamine. In addition to its role as a transcrip-
tional regulator of the antioxidant response pathway, Nrf2 positively
regulated autophagy and is an essential component of regulatory
networks that respond to different types of stress, including protein
aggregation, nutrient deﬁciency, and viral infection. Although previ-
ously reported that SFN action is dependent on ROS production in
PC-3 cells,44 we demonstrated that SFN alone did not stimulate
ROS accumulation and the effects of SFN on Nrf2 activity and
VSVD51-induced infectivity were independent of ROS. Activation
of Nrf2 by SFN was previously shown to be independent of ROS,
because SFN directly binds to cysteine residues within the Nrf2
repressor Keap1 in vitro,34,45 with C151 serving as the main sensor
cysteine.46,47
The Nrf2-regulated gene HO-1 was one of the Nrf2-regulated
activities responsible for the induction of autophagy. It is possible
that HO-1 activates autophagy via the ataxia telangiectasia mutated
(ATM) protein, which triggers autophagy by inhibiting mTORC1.48
Nrf2 positively regulates ATM during cell stress, and ATM is acti-
vated by the accumulation of carbon monoxide, a product of HO-1
catalysis.49 Thus, HO-1 may activate autophagy through the pro-
duction of carbon monoxide, which then activates ATM, inhibits
mTORC1, and facilitates autophagy. In support of this idea, blockade
of type I IFN production by rapamycin inhibited mTORC1 and
potentiated the oncolytic activity of VSVD51.50 Consistent with the
preceding idea, the mTOR pathway was inhibited following SFN
treatment in PC-3 cells (D.O., unpublished data), and SFNwas shown
to induce autophagy through the inhibition of mechanistic target of
rapamycin (mTOR) in primary murine hepatocytes.51 Because inhi-
bition of mTOR is crucial to the potentiation of VSVD51 oncolysis,50
further studies are required to investigate the relationship between
mTOR signaling and stimulation of VSVD51 replication by SFN.
In addition to suppression of the innate antiviral response, stimula-
tion of the adaptive immune response by OV infection is an essential
part of a curative response.4,52–54 Cancer cells reside in the com-
plex host-tumor microenvironment and have evolved to suppress
signaling to the adaptive immune system to evade T cell-mediated
detection and destruction.3,4,54 By dampening the innate antiviral
response using oncolytic adjuvants, VSVD51 and other OVs replicate
more robustly within the tumor mass, increase inﬂammation in the
tumor bed, and facilitate an adaptive T cell-mediated response against
tumor antigens via cross presentation.52,54–56 Although more detailed
mechanistic studies are required to investigate the effects of SFN
in vivo, we speculate that SFN enhances the therapeutic effect of
VSVD51 in tumor models by a similar mechanism. We also speculate
that the small tumor volumes associated with the TS/A model in
BALB/c mice correlated with the immunocompetent environment
that targeted the TS/A tumor cells, in contrast to the immunodeﬁcient
environment associated with the PC-3-nude mouse model. Our re-
sults, along with numerous other studies, demonstrate that combina-
torial oncolytic virotherapy culminates in multiple mechanisms
of tumor killing: direct virus-mediated cell death, stimulation of
inﬂammation within the tumor, and induction of a targeted adaptive
immune response.2,54,57
The cancer cell line most susceptible to VSVD51-mediated cell
killing was the human lung epithelial A549 line that harbors a point
mutation inactivating Keap1, thus increasing Nrf2 nuclear transloca-
tion and transcriptional activity.31 High levels of Nrf2 correlate with
poor prognosis, and often patients bearing tumors with high
amounts of nuclear Nrf2 are resistant to chemotherapy and radiation
therapy.31 An OV approach could be advantageous in patients with
chemo- and radio-resistant Nrf2-associated tumors, because OV ac-
tivity may be preferentially increased in this subset of tumors. Our
studies are being directed toward establishing correlations among
Nrf2 activation, antiviral suppression, and susceptibility to OV repli-
cation in tumors bearing mutations of the Nrf2/Keap1 axis. With
regard to the transition of this and related combinatorial strategies
to the clinic, both OVs and SFN are being evaluated as monothera-
pies in clinical trials. SFN, at concentrations that are achievable
in vivo, has been shown to be non-toxic to healthy cells,26,58,59 and
mice exhibited no visible adverse effects to SFN; likewise, OV admin-
istration is well tolerated in multiple clinical trials.2,57 Although we
demonstrated that the SFN-mediated inhibition of the antiviral re-
sponses and enhanced OV efﬁcacy is tumor cell speciﬁc, investiga-
tion of this promising combination approach could facilitate clinical
implementation of OVs as therapeutic agents for the treatment of a
variety of cancer types.
Collectively, our data demonstrate that SFN stimulates an Nrf2-regu-
lated, multi-functional, transcriptional network that, in the context of
virus infection, leads to the induction of autophagy, suppression of
the IFN-mediated antiviral response, and subsequent enhancement
of VSVD51 replication and tumor cell death. Furthermore, our
ﬁndings reveal a previously unappreciated role for Nrf2 in control-
ling VSVD51 replication that could ultimately provide to patients
with Nrf2-associated tumors an alternative form of immune-based
therapy.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
Human PC-3 and A549 cell lines were obtained from the American
Type Culture Collection (ATCC). PC-3 and A549 cells were
cultured in F12K medium (Wisent) supplemented with 10% fetal
bovine serum (FBS, Wisent) and 1% antibiotics (Sigma-Aldrich).
HEK293T cells were also obtained from ATCC and cultured in
DMEM (Wisent) supplemented with 10% FBS and 1% antibiotics.
TS/A cells (murine mammary adenocarcinoma) cultured in DMEM
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supplemented with 10% FBS and 1% antibiotics were a gift from Dr.
Glen Barber (University of Miami). MDA-MB-231 (mammary
adenocarcinoma) human cells and Vero cells were provided by Drs.
Josie Ursini-Siegel and Mark Wainberg, respectively (Lady Davis
Institute) and were grown in DMEM, 10% FBS, and 1% antibiotics.
Human U-2 OS cells were obtained fromDr. Sonia Rocha (University
of Dundee) and were cultured in DMEM (Gibco) that contains
L-glutamine, high D-glucose (4.5 g/L), and phenol red supplemented
with 10% (v/v) FBS (Thermo Scientiﬁc). MRC-5 cells (human normal
lung ﬁbroblast) were obtained from Dr. Jerry Pelletier (McGill
University) and cultured in DMEM supplemented with 10% FBS
and 1% antibiotics.
WT, Keap1-knockout (Keap1/), and Nrf2-knockout (Nrf2/)
MEFs were obtained fromDr.Masayuki Yamamoto (TohokuUniver-
sity). MEF cell lines were generated from day 13.5 embryos of WT,
Nrf2/, and Keap1/ C57BL/6 mice60,61 and were cultured as pre-
viously described.62WTAtg5 (Atg5+/+) andAtg5-knockout (Atg5/)
MEFs were a gift from Dr. Yu-Ying He (University of Chicago) and
were originally produced by Dr. Noboru Mizushima.63 MEF cells
were cultured in DMEM supplemented with 10% FBS and 1% anti-
biotics. All cell lines were incubated at 37C in a humidiﬁed atmo-
sphere of 5% CO2 and 95% air.
Drugs and Cytokine
SFN and DEM were purchased from Santa Cruz Biotechnology and
dissolved in DMSO and 95% ethanol, respectively. 3-MeA, L-NAC,
pyocyanin, and H2O2 were purchased from Sigma-Aldrich. The
pH of the L-NAC solution was adjusted to 7. IFN-a2b was obtained
from Merck.
VSV Production, Quantification, and Infection
VSVD51-expressing GFP is a recombinant derivative of the VSV
Indiana serotype described previously.18 The virus was provided by
Drs. John Bell and David Stojdl (Ottawa Health Research Institute).
VSVD51 was propagated on Vero cells, and virus titers were quanti-
ﬁed by a standard plaque assay method on Vero cells as described
previously.9,10
In Vitro Treatment with Drugs and Infection with VSVD51
Cancer cell lines or MEFs were pretreated for 24 hr with SFN. Sub-
sequently, cells were infected at indicated MOIs with VSVD51 for
the indicated periods. The cells were imaged with the ZOE Fluores-
cent Cell Imager (Bio-Rad). The percentage of cells infected with
VSVD51 was determined based on GFP expression using a BD LSR
Fortessa cell analyzer (Becton Dickinson); calculations, as well as
population analyses, were done using FACSDiva.
Flow Cytometry
Cell Viability and Apoptosis Analyses
Cell viability and apoptosis were assessed as previously reported64
by ﬂow cytometry and were based on the measurement of phos-
phatidylserine externalization at the cell surface using a speciﬁc
annexin-V antibody.
Total and Mitochondrial ROS Production
Total ROS and mitochondrial-dependent ROS using CM-H2DCFDA
(1 mM) and MitoSOX Red Mitochondrial Superoxide Indicator
(0.5 mM, Life Technologies) were evaluated by ﬂow cytometry.
Following SFN treatment and/or VSVD51 infection, cells were
washed in PBS before incubation with the different probes for
30 min at 37C. After incubation, cells were washed twice in PBS
before ﬂuorescence-activated cell sorting (FACS) analysis.
Nrf2 Phosflow
Phospho-Nrf2 staining was performed in a 96-well plate format.
Cells were resuspended in 100 mL of PBS and ﬁxed with the same vol-
ume of prewarmed Fix Buffer I (BD Biosciences) for 10 min at 37C.
Cells were pelleted down by centrifugation and resuspended in
200 mL ice-cold Perm Buffer III (BD Biosciences) for 20 min at
4C. Cells were then washed three times with 200 mL of PBS contain-
ing 5% FBS and incubated for 30 min on ice in PBS containing 2%
FBS. Cells were pelleted down by centrifugation and stained in
100 mL PBS containing 2% FBS with a rabbit monoclonal phospho-
S40-Nrf2 antibody (ab76026, Abcam) for 30 min at room tempera-
ture (RT). Cells were washed twice in staining buffer and stained
with an Alexa Fluor 488 (AF488)-conjugated goat antirabbit second-
ary antibody (ab150077, Abcam) for an extra 30 min at RT. After two
more washes using the staining buffer, cells were analyzed by ﬂow
cytometry.
Protein Extraction and Immunoblot Analysis
Cells were washed twice with ice-cold PBS and lysed in ice-cold buffer
containing 10% glycerol, 20 mMTris-HCl (pH 7.5), 1% Triton X-100,
5 mM NaF, 40 mM b-glycerophosphate, 1 mM Na3VO4, 150 mM
NaCl, 1 mM PMSF, 1 mMDTT, 10 mMNEM, and protease inhibitor
cocktail (Sigma-Aldrich). Lysed extracts were kept on ice for 30 min
and centrifuged at 10,000  g for 15 min at 4C. Then, 20–40 mg of
clariﬁed whole-cell lysates were separated by SDS-PAGE on 4%–
12% precast gradient gels (Bio-Rad). Proteins were electrophoreti-
cally transferred to a nitrocellulose membrane (0.45 mM, Bio-Rad)
for 1 hr at 100 V in a buffer containing 30 mM Tris, 200 mM glycine,
and 20% ethanol. Blots were blocked for 1 hr with 5% nonfat dried
milk in PBST (PBS + 0.1% Tween 20) and then probed overnight
at 4C with any of the following speciﬁc primary antibodies: VSV-
whole virus antisera, anti-GFP (sc-9996, Santa Cruz), anticleaved
caspase-3 (9661, Cell Signal), anti-caspase-7/cleaved caspase-7
(9494, Cell Signal), anti-PARP/cleaved PARP (9541, Cell Signal),
anti-Nrf2 (ab62352, Abcam; 12721, Cell Signal), anti-HO-1 (5853,
Cell Signal), anti-P-IRF3 (4947, Cell Signal), anti-IRF3 (ab68481,
Abcam), anti-P-STAT1 (9167, Cell Signal), anti-STAT1 (sc-417,
Santa Cruz), anti-RIG-I (Bleed, Millipore), anti-STING (13647, Cell
Signal), anti-LC3B (2775, Cell Signal), anti-Atg7 (8558, Cell Signal),
and anti-actin (MAB1501, Millipore) used as loading control. After
three washes in PBST, antibody signals were detected by chemilumi-
nescence using secondary mouse or rabbit antibodies conjugated to
horseradish peroxidase (Mandel) and an enhanced chemilumines-
cence (ECL) detection kit as per manufacturer’s instructions (Thermo
Scientiﬁc).
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RNA Extraction and High-Throughput qPCR Assay
RNA extraction and high-throughput qPCR BioMark assay were
performed as described previously.65,66 The sequences of primers
used, as well as their complementary probes, are available upon
request or can be seen in Olagnier et al.66
Nuclear Protein Extraction and IRF3 DNA-Binding Activity
Nuclear and cytoplasmic proteins were isolated using the following
protocol. Cells were lysed in a 400 mL solution containing 10 mM
Tris, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% protease
inhibitor, 1 mM DTT, 1 mM PMSF, 10 mM sodium orthovanadate,
20 mM NaF, and 40 mM b-glycerophosphate at 4C. After 15 min,
25 mL of 10% NP40 was added, and the solution was centrifuged
at maximum speed for 5 min. The supernatant was collected and
kept as the cytoplasmic fraction. The pellet was washed once more
in the previously mentioned lysis solution and then lysed with
25 mL of another lysis solution containing 20 mM Tris, 400 nM
NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% protease inhibitor, 1 mM
PMSF, and 40 mM b-glycerophosphate at 4C while vortexing. After
1 hr, the solution was centrifuged at max speed for 15 min, and the
supernatant was kept as the nuclear extract. At least 10 mg of protein
were loaded per gel. IRF3 TransAM ELISA kit (Active Motif) was
used to evaluate IRF3 DNA-binding activity as per manufacturer’s
recommendations.
Plasmid Constructs
Plasmids encoding ISRE-Luc and pRLTK have been described
previously.67,68 The pP-ARE-Luciferase reporter plasmid bearing
the ARE of human Nqo1 gene was a gift from Dr. Alexander Ivanov
(Engelhardt Institute of Molecular Biology, Russian Academy of
Sciences).69 The Nrf2 overexpression plasmid was provided by
Dr.VolkerBlank (LadyDavis Institute) andwas describedpreviously.70
The HO-1 overexpression plasmid was provided by Dr. Hyman Schip-
per (Lady Davis Institute) and was described previously.71
Luciferase Assay
For ISRE-Luc assays, experiments were performed as previously
reported using the calcium phosphate transfection method.68 For
ARE luciferase assays, HEK293T cells were transfected with 50 ng
of pRLTK reporter plasmid, 100 ng of pP-ARE-Luc reporter, and
increasing doses of the expression plasmid encoding for Nrf2 or
HO-1, along with the appropriate amount of empty vector, by the cal-
cium phosphate transfection method. After 24 hr of transfection,
luciferase activity was measured with a dual-luciferase reporter assay
and a GloMax 20/20 luminometer according to the manufacturer’s
recommendations (Promega).
Transfection and siRNA
For siRNA experiments, A549 cells were transfected with 75 pmol of
human Nrf2 (sc-37030), HO-1 (sc-35554), Atg7 (sc-41447), or con-
trol siRNA (sc-37007) diluted in Opti-MEM (Thermo Scientiﬁc)
and using Lipofectamine RNAi Max as per manufacturer’s instruc-
tions. A549 cells were incubated for 48 hr in the presence of the
siRNA before being challenged with VSVD51.
Immunofluorescence
U-2 OS cells (2.5  105) were seeded on 1.5 mm thick, 18 by
18 mm glass coverslips (VWR); placed in each well of a 6-well plate;
and treated with either vehicle [0.1% (v/v) DMSO] or SFN for
24 hr. After 20 to 24 hr, the cells were washed three times with
37C prewarmed PBS, ﬁxed with ice-cold methanol (20C) for
15 min, and permeabilized with 0.1% Triton X-100 in PBS
(PBS-Tx) for a further 15 min. Next, the cells were placed in block-
ing solution (3% normal donkey serum in PBS-Tx) for 30 min at
RT, after which they were incubated for 1–1.5 hr at RT with mouse
anti-p62 (1:400, Abcam) or rabbit anti-LC3BII (1:200, Cell Signal)
antibodies diluted in the blocking solution. After three washes
every 5 min using PBS-Tx, the cells were incubated for 1 hr in
the dark with Alexa Fluor 594 nm ﬂuorophore-conjugated antirab-
bit (1:400) and Alexa Fluor 680 nm ﬂuorophore-conjugated anti-
mouse (1:400) secondary antibodies (Jackson ImmunoResearch)
diluted in the blocking solution. After washing three times every
5 min using PBS-Tx and a further 5 min wash with PBS, the cells
were incubated with DAPI (dissolved in PBS at a ﬁnal concentra-
tion of 2.5 mg/mL) for 5 min at RT in the dark. The cells were
quickly washed three times with PBS, mounted onto frosted glass
slides (VWR) using 30 mL of ProLong gold antifade mounting me-
dium (Invitrogen), and left to cure overnight at RT. On the
following day, the cells were imaged using wideﬁeld microscope
(Deltavision Elite, GE Healthcare). The data shown represent the
maximum intensity projection of 25 optical sections obtained
with 0.2 mm thickness per section.
In Vivo Tumor Models
TS/A Model
8-week-old-female BALB/c mice obtained from Charles River Labo-
ratories were injected s.c. with 3  105 TS/A cells suspended in
100 mL PBS (n = 7 animals per group). Approximately 7 days later,
when tumors became palpable (100–150 mm3), tumors were injected
with 2 107 PFU of VSVD51-GFP (in 75 mL of PBS) on day 0 and day
4. SFN at 10 mg/kg was administered i.p. 1 day before the ﬁrst
VSVD51 injection and then on days 1, 4, and 6 following the ﬁrst
VSVD51 administration. Tumors sizes were measured at the indi-
cated time points using an electronic caliper, and tumor volume
was calculated as length  (width)2/2. To account for variable tumor
size at the beginning of the experiment, tumor volume was normal-
ized to its initial volume on day 0 and presented as a percentage.
For survival studies, mice were euthanized when tumors had reached
2,000 mm3 or presented evidence of necrosis or sepsis at the tumor
site. Log rank (Mantel-Cox) tests were performed on Kaplan-Meier
survival graphs using Prism 5 (GraphPad). To assess for the safety
of the combinatorial treatment, mice were weighed every 2 days until
day 8.
PC-3 Model
10-week-old-male athymic nude mice obtained from Charles River
Laboratories were injected s.c. with 5  106 human PC-3 cells
(n = 7 animals per group). Four weeks later, when tumors reached
100–150 mm3, mice were treated intratumorally ( i.t.) with
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VSVD51-GFP (2  107) on days 0, 3, 6, 9, and 12 and i.p. every day
with SFN (10 mg/kg) from day 1 to day 10. Tumor sizes were
measured using an electronic caliper. Tumor volume and survival
were determined as described previously. All experiments were per-
formed in accordance with the Lady Davis Institute-McGill Univer-
sity Animal Care and Veterinary Services guidelines under protocol
2007-5212.
Statistical Analysis
Values were expressed as the mean ± SEM. Graphs and statistics
were computed using Microsoft Excel or GraphPad Prism 5. An un-
paired, two-tailed Student’s t test was used to determine signiﬁcance
of the difference between the control and each experimental condi-
tion. The p values of less than 0.05 were considered statistically sig-
niﬁcant: ***p < 0.001, **p < 0.01, and *p < 0.05. The log rank
(Mantel-Cox) test was used to determine signiﬁcant differences in
plots for mice survival studies. A two-way ANOVA analysis was
used to calculate signiﬁcant differences in plots for tumor growth
studies.
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